請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52754完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳青周 | |
| dc.contributor.author | Ruo-Yu Tseng | en |
| dc.contributor.author | 曾若瑜 | zh_TW |
| dc.date.accessioned | 2021-06-15T16:26:08Z | - |
| dc.date.available | 2020-09-24 | |
| dc.date.copyright | 2015-09-24 | |
| dc.date.issued | 2015 | |
| dc.date.submitted | 2015-08-14 | |
| dc.identifier.citation | Alex, P., Zachos, N. C., Nguyen, T., Gonzales, L., Chen, T. E., Conklin, L. S., . . . Li, X. (2009). Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis, 15(3), 341-352. doi: 10.1002/ibd.20753 Aparicio, L. A., Valladares, M., Blanco, M., Alonso, G., Figueroa, A. (2012). Biological influence of Hakai in cancer: a 10-year review. Cancer and Metastasis Reviews, 31(1-2), 375-386. doi: DOI 10.1007/s10555-012-9348-x Arcila, M. E., Nafa, K., Chaft, J. E., Rekhtman, N., Lau, C., Reva, B. A., . . . Ladanyi, M. (2013). EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther, 12(2), 220-229. doi: 10.1158/1535-7163.MCT-12-0620 Baumgart, D. (2012). Crohn's disease and ulcerative colitis : from epidemiology and immunobiology to a rational diagnostic and therapeutic approach. New York: Springer. Blum, A., Shamburek, R. (2009). The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis, 203(2), 325-330. doi: DOI 10.1016/j.atherosclerosis.2008.08.022 Bolden, J. E., Peart, M. J., Johnstone, R. W. (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov, 5(9), 769-784. doi: 10.1038/nrd2133 Cardwell, C. R., Mc Menamin, U., Hughes, C. M., Murray, L. J. (2015). Statin Use and Survival from Lung Cancer: A Population-Based Cohort Study. Cancer Epidemiology Biomarkers Prevention, 24(5), 833-841. doi: Doi 10.1158/1055-9965.Epi-15-0052 Chan, B. A., Hughes, B. G. (2015). Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res, 4(1), 36-54. doi: 10.3978/j.issn.2218-6751.2014.05.01 Chan, K. K. W., Oza, A. M., Siu, L. L. (2003). The statins as anticancer agents. Clinical Cancer Research, 9(1), 10-19. Chen, J. B., Chern, T. R., Wei, T. T., Chen, C. C., Lin, J. H., Fang, J. M. (2013). Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment. J Med Chem, 56(9), 3645-3655. doi: 10.1021/jm400179b Cho, J. H. (2008). The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol, 8(6), 458-466. doi: 10.1038/nri2340 Chuang, D. M., Leng, Y., Marinova, Z., Kim, H. J., Chiu, C. T. (2009). Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci, 32(11), 591-601. doi: 10.1016/j.tins.2009.06.002 Clendening, J. W., Penn, L. Z. (2012). Targeting tumor cell metabolism with statins. Oncogene, 31(48), 4967-4978. doi: 10.1038/onc.2012.6 Cross, D. A., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., . . . Pao, W. (2014). AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discovery, 4(9), 1046-1061. doi: 10.1158/2159-8290.CD-14-0337 Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., . . . Futreal, P. A. (2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 949-954. doi: 10.1038/nature00766 de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S., van Kuilenburg, A. B. (2003). Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J, 370(Pt 3), 737-749. doi: 10.1042/BJ20021321 Demierre, M. F., Higgins, P. D., Gruber, S. B., Hawk, E., Lippman, S. M. (2005). Statins and cancer prevention. Nat Rev Cancer, 5(12), 930-942. doi: 10.1038/nrc1751 Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., . . . Hillan, K. J. (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol, 23(25), 5900-5909. doi: 10.1200/JCO.2005.02.857 Edge, S. B., Compton, C. C. (2010). The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Annals of Surgical Oncology, 17(6), 1471-1474. doi: DOI 10.1245/s10434-010-0985-4 Egger, B., Bajaj-Elliott, M., MacDonald, T. T., Inglin, R., Eysselein, V. E., Buchler, M. W. (2000). Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion, 62(4), 240-248. doi: 7822 Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., . . . Janne, P. A. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316(5827), 1039-1043. doi: 10.1126/science.1141478 Esteller, M. (2006). The necessity of a human epigenome project. Carcinogenesis, 27(6), 1121-1125. doi: 10.1093/carcin/bgl033 Fenton, R. G., Kung, H. F., Longo, D. L., Smith, M. R. (1992). Regulation of intracellular actin polymerization by prenylated cellular proteins. J Cell Biol, 117(2), 347-356. Figueiredo, L. M., Cross, G. A., Janzen, C. J. (2009). Epigenetic regulation in African trypanosomes: a new kid on the block. Nat Rev Microbiol, 7(7), 504-513. doi: 10.1038/nrmicro2149 Frederick, B. A., Helfrich, B. A., Coldren, C. D., Zheng, D., Chan, D., Bunn, P. A., Jr., Raben, D. (2007). Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther, 6(6), 1683-1691. doi: 10.1158/1535-7163.MCT-07-0138 Glauben, R., Batra, A., Fedke, I., Zeitz, M., Lehr, H. A., Leoni, F., . . . Siegmund, B. (2006). Histone hyperacetylation is associated with amelioration of experimental colitis in mice. Journal of Immunology, 176(8), 5015-5022. Goldstein, J. L., Brown, M. S. (1990). Regulation of the mevalonate pathway. Nature, 343(6257), 425-430. doi: 10.1038/343425a0 Gong, Y., Yao, E., Shen, R., Goel, A., Arcila, M., Teruya-Feldstein, J., . . . Pao, W. (2009). High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One, 4(10), e7273. doi: 10.1371/journal.pone.0007273 Graff, J. R., Herman, J. G., Lapidus, R. G., Chopra, H., Xu, R., Jarrard, D. F., . . . Baylin, S. B. (1995). E-Cadherin Expression Is Silenced by DNA Hypermethylation in Human Breast and Prostate Carcinomas. Cancer Res, 55(22), 5195-5199. Grant, S., Easley, C., Kirkpatrick, P. (2007). Vorinostat. Nat Rev Drug Discov, 6(1), 21-22. doi: 10.1038/nrd2227 Gray-Bablin, J., Rao, S., Keyomarsi, K. (1997). Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res, 57(4), 604-609. Greulich, H., Chen, T. H., Feng, W., Janne, P. A., Alvarez, J. V., Zappaterra, M., . . . Meyerson, M. (2005). Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med, 2(11), e313. doi: 10.1371/journal.pmed.0020313 Halme, L., Paavola-Sakki, P., Turunen, U., Lappalainen, M., Farkkila, M., Kontula, K. (2006). Family and twin studies in inflammatory bowel disease. World J Gastroenterol, 12(23), 3668-3672. Herbst, R. S., Heymach, J. V., Lippman, S. M. (2008). Lung cancer. N Engl J Med, 359(13), 1367-1380. doi: 10.1056/NEJMra0802714 Holohan, C., Van Schaeybroeck, S., Longley, D. B., Johnston, P. G. (2013). Cancer drug resistance: an evolving paradigm. Nat Rev Cancer, 13(10), 714-726. doi: 10.1038/nrc3599 Hrabeta, J., Stiborova, M., Adam, V., Kizek, R., Eckschlager, T. (2014). Histone deacetylase inhibitors in cancer therapy. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 158(2), 161-169. doi: 10.5507/bp.2013.085 Huang, E. H., Wicha, M. S. (2008). Colon cancer stem cells: implications for prevention and therapy. Trends Mol Med, 14(11), 503-509. doi: 10.1016/j.molmed.2008.09.005 Huber, M. A., Kraut, N., Beug, H. (2005). Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol, 17(5), 548-558. doi: 10.1016/j.ceb.2005.08.001 Hynes, M. J., Huang, K. M., Huang, E. H. (2009). Review paper: Implications of the 'cancer stem cell' hypothesis on murine models of colon cancer and colitis-associated cancer. Vet Pathol, 46(5), 819-835. doi: 10.1354/vp.08-VP-0172-H-REV Janku, F., Stewart, D. J., Kurzrock, R. (2010). Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol, 7(7), 401-414. doi: 10.1038/nrclinonc.2010.64 Janne, P. A. (2005). Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations. Semin Oncol, 32(6 Suppl 10), S9-15. doi: 10.1053/j.seminoncol.2005.10.004 Janne, P. A., Yang, J. C., Kim, D. W., Planchard, D., Ohe, Y., Ramalingam, S. S., . . . Ranson, M. (2015). AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med, 372(18), 1689-1699. doi: 10.1056/NEJMoa1411817 Kalluri, R., Weinberg, R. A. (2009). The basics of epithelial-mesenchymal transition. J Clin Invest, 119(6), 1420-1428. doi: 10.1172/JCI39104 Kanai, Y., Ushijima, S., Hui, A. M., Ochiai, A., Tsuda, H., Sakamoto, M., Hirohashi, S. (1997). The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. International Journal of Cancer, 71(3), 355-359. Kaser, A., Zeissig, S., Blumberg, R. S. (2010). Inflammatory bowel disease. Annu Rev Immunol, 28, 573-621. doi: 10.1146/annurev-immunol-030409-101225 Keyomarsi, K., Sandoval, L., Band, V., Pardee, A. B. (1991). Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res, 51(13), 3602-3609. la Sala, A., Pontecorvo, L., Agresta, A., Rosano, G., Stabile, E. (2012). Regulation of collateral blood vessel development by the innate and adaptive immune system. Trends Mol Med, 18(8), 494-501. doi: 10.1016/j.molmed.2012.06.007 Lane, A. A., Chabner, B. A. (2009). Histone deacetylase inhibitors in cancer therapy. J Clin Oncol, 27(32), 5459-5468. doi: 10.1200/JCO.2009.22.1291 Lee, H. J., Schaefer, G., Heffron, T. P., Shao, L., Ye, X., Sideris, S., . . . Settleman, J. (2013). Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discovery, 3(2), 168-181. doi: 10.1158/2159-8290.CD-12-0357 Levayer, R., Lecuit, T. (2008). Breaking down EMT. Nat Cell Biol, 10(7), 757-759. doi: 10.1038/ncb0708-757 Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., . . . Wong, K. K. (2008). BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 27(34), 4702-4711. doi: 10.1038/onc.2008.109 Lin, Y. C., Lin, J. H., Chou, C. W., Chang, Y. F., Yeh, S. H., Chen, C. C. (2008). Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res, 68(7), 2375-2383. doi: Doi 10.1158/0008-5472.Can-07-5807 Linardou, H., Dahabreh, I. J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., . . . Murray, S. (2008). Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncology, 9(10), 962-972. doi: Doi 10.1016/S1470-2045(08)70206-7 Liu, H., Wang, Z., Li, Y., Li, W., Chen, Y. (2013). Simvastatin prevents proliferation and bone metastases of lung adenocarcinoma in vitro and in vivo. Neoplasma, 60(3), 240-246. doi: 10.4149/neo_2013_032 Loftus, E. V., Jr. (2004). Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology, 126(6), 1504-1517. Luger, K. (2003). Structure and dynamic behavior of nucleosomes. Curr Opin Genet Dev, 13(2), 127-135. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., . . . Haber, D. A. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350(21), 2129-2139. doi: 10.1056/NEJMoa040938 Melgar, S., Karlsson, A., Michaelsson, E. M. (2005). Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. American Journal of Physiology-Gastrointestinal and Liver Physiology, 288(6), G1328-G1338. doi: DOI 10.1152/ajpgi.00467.2004 Molodecky, N. A., Soon, I. S., Rabi, D. M., Ghali, W. A., Ferris, M., Chernoff, G., . . . Kaplan, G. G. (2012). Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 142(1), 46-54 e42; quiz e30. doi: 10.1053/j.gastro.2011.10.001 Munster, P. N., Marchion, D., Thomas, S., Egorin, M., Minton, S., Springett, G., . . . Daud, A. (2009). Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. British Journal of Cancer, 101(7), 1044-1050. doi: DOI 10.1038/sj.bjc.6605293 Murthy, S. N., Cooper, H. S., Shim, H., Shah, R. S., Ibrahim, S. A., Sedergran, D. J. (1993). Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci, 38(9), 1722-1734. Nightingale, K. P., O'Neill, L. P., Turner, B. M. (2006). Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr Opin Genet Dev, 16(2), 125-136. doi: 10.1016/j.gde.2006.02.015 Okamoto, W., Okamoto, I., Tanaka, K., Hatashita, E., Yamada, Y., Kuwata, K., . . . Nakagawa, K. (2010). TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther, 9(10), 2785-2792. doi: 10.1158/1535-7163.MCT-10-0481 Okayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., Inagaki, Y., Nakaya, R. (1990). A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology, 98(3), 694-702. Oxnard, G. R., Lo, P. C., Nishino, M., Dahlberg, S. E., Lindeman, N. I., Butaney, M., . . . Janne, P. A. (2013). Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol, 8(2), 179-184. doi: 10.1097/JTO.0b013e3182779d18 Pao, W., Chmielecki, J. (2010). Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer, 10(11), 760-774. doi: 10.1038/nrc2947 Pao, W., Girard, N. (2011). New driver mutations in non-small-cell lung cancer. Lancet Oncol, 12(2), 175-180. doi: 10.1016/S1470-2045(10)70087-5 Pao, W., Kris, M. G., Iafrate, A. J., Ladanyi, M., Janne, P. A., Wistuba, I. I., . . . Lynch, T. J. (2009). Integration of Molecular Profiling into the Lung Cancer Clinic. Clinical Cancer Research, 15(17), 5317-5322. doi: Doi 10.1158/1078-0432.Ccr-09-0913 Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., . . . Varmus, H. E. (2005). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med, 2(1), e17. doi: 10.1371/journal.pmed.0020017 Pearson, F. G. (1999). Non-small cell lung cancer: role of surgery for stages I-III. Chest, 116(6 Suppl), 500S-503S. Pece, S., Gutkind, J. S. (2002). E-cadherin and Hakai: signalling, remodeling or destruction? Nat Cell Biol, 4(4), E72-74. doi: 10.1038/ncb0402-e72 Peinado, H., Olmeda, D., Cano, A. (2007). Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer, 7(6), 415-428. doi: 10.1038/nrc2131 Peng, X. D., Wu, X. H., Chen, L. J., Wang, Z. L., Hu, X. H., Song, L. F., . . . Wei, Y. Q. (2010). Inhibition of phosphoinositide 3-kinase ameliorates dextran sodium sulfate-induced colitis in mice. J Pharmacol Exp Ther, 332(1), 46-56. doi: 10.1124/jpet.109.153494 Rao, S., Porter, D. C., Chen, X., Herliczek, T., Lowe, M., Keyomarsi, K. (1999). Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A, 96(14), 7797-7802. Riely, G. J., Marks, J., Pao, W. (2009). KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc, 6(2), 201-205. doi: 10.1513/pats.200809-107LC Roth, S. Y., Denu, J. M., Allis, C. D. (2001). Histone acetyltransferases. Annu Rev Biochem, 70, 81-120. doi: 10.1146/annurev.biochem.70.1.81 Saito, Y., Takazawa, H., Uzawa, K., Tanzawa, H., Sato, K. (1998). Reduced expression of E-cadherin in oral squamous cell carcinoma: Relationship with DNA methylation of 5 ' CpG island. International Journal of Oncology, 12(2), 293-298. Sasaki, M., Bharwani, S., Jordan, P., Joh, T., Manas, K., Warren, A., . . . Alexander, J. S. (2003). The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. J Pharmacol Exp Ther, 305(1), 78-85. doi: 10.1124/jpet.102.044099 Sasaki, T., Rodig, S. J., Chirieac, L. R., Janne, P. A. (2010). The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer, 46(10), 1773-1780. doi: 10.1016/j.ejca.2010.04.002 Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., . . . Gandara, D. (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 26(21), 3543-3551. doi: 10.1200/JCO.2007.15.0375 Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., . . . Eastern Cooperative Oncology, G. (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346(2), 92-98. doi: 10.1056/NEJMoa011954 Sharma, S. V., Bell, D. W., Settleman, J., Haber, D. A. (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 7(3), 169-181. doi: 10.1038/nrc2088 Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., . . . Settleman, J. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell, 141(1), 69-80. doi: 10.1016/j.cell.2010.02.027 Shi, Y. (2007). Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet, 8(11), 829-833. doi: 10.1038/nrg2218 Siegel, R. L., Miller, K. D., Jemal, A. (2015). Cancer statistics, 2015. CA Cancer J Clin, 65(1), 5-29. doi: 10.3322/caac.21254 Siegelin, M. D., Borczuk, A. C. (2014). Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Invest, 94(2), 129-137. doi: 10.1038/labinvest.2013.147 Simpson, K. J., Dugan, A. S., Mercurio, A. M. (2004). Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma. Cancer Res, 64(23), 8694-8701. doi: 10.1158/0008-5472.CAN-04-2247 Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., . . . Rosen, N. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature, 439(7074), 358-362. doi: 10.1038/nature04304 Soria, J. C., Mok, T. S., Cappuzzo, F., Janne, P. A. (2012). EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer Treat Rev, 38(5), 416-430. doi: 10.1016/j.ctrv.2011.10.003 Spira, A., Ettinger, D. S. (2004). Multidisciplinary management of lung cancer. N Engl J Med, 350(4), 379-392. doi: 10.1056/NEJMra035536 Talley, N. J., Abreu, M. T., Achkar, J. P., Bernstein, C. N., Dubinsky, M. C., Hanauer, S. B., . . . American College of Gastroenterology, I. B. D. T. F. (2011). An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol, 106 Suppl 1, S2-25; quiz S26. doi: 10.1038/ajg.2011.58 Thiery, J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer, 2(6), 442-454. doi: 10.1038/nrc822 Thiery, J. P., Acloque, H., Huang, R. Y., Nieto, M. A. (2009). Epithelial-mesenchymal transitions in development and disease. Cell, 139(5), 871-890. doi: 10.1016/j.cell.2009.11.007 Thomas, A., Liu, S. V., Subramaniam, D. S., Giaccone, G. (2015). Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol. doi: 10.1038/nrclinonc.2015.90 Thurn, K. T., Thomas, S., Moore, A., Munster, P. N. (2011). Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncology, 7(2), 263-283. doi: Doi 10.2217/Fon.11.2 Thurnher, M., Nussbaumer, O., Gruenbacher, G. (2012). Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents. Clinical Cancer Research, 18(13), 3524-3531. doi: Doi 10.1158/1078-0432.Ccr-12-0489 Tollefsbol, T. O. (2009). Cancer epigenetics. Boca Raton: CRC Press. Voldborg, B. R., Damstrup, L., Spang-Thomsen, M., Poulsen, H. S. (1997). Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol, 8(12), 1197-1206. Wachtershauser, A., Akoglu, B., Stein, J. (2001). HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis, 22(7), 1061-1067. Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., . . . Allen, A. (2013). Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC. Cancer Discovery, 3(12), 1404-1415. doi: Doi 10.1158/2159-8290.Cd-13-0314 Wang, G. G., Allis, C. D., Chi, P. (2007). Chromatin remodeling and cancer, Part I: Covalent histone modifications. Trends Mol Med, 13(9), 363-372. doi: 10.1016/j.molmed.2007.07.003 Weisenburger, T. H. (1994). Effects of Postoperative Mediastinal Radiation on Completely Resected Stage-Ii and Stage-Iii Epidermoid Cancer of the Lung - Lcsg-773. Chest, 106(6), S297-S301. doi: DOI 10.1378/chest.106.6.297S West, A. C., Johnstone, R. W. (2014). New and emerging HDAC inhibitors for cancer treatment. J Clin Invest, 124(1), 30-39. doi: 10.1172/JCI69738 Witta, S. E., Gemmill, R. M., Hirsch, F. R., Coldren, C. D., Hedman, K., Ravdel, L., . . . Bunn, P. A., Jr. (2006). Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res, 66(2), 944-950. doi: 10.1158/0008-5472.CAN-05-1988 Witta, S. E., Helfrich, B., Chan, D., Hirsch, F., Franklin, W., Drabkin, H. A., . . . Bunn, P. A. (2005). Overcoming resistance to EGFR inhibitors in NSCLC cell lines by sequential treatment with histone deacetylase inhibitors. Journal of Clinical Oncology, 23(16), 641s-641s. Wu, C. Y., Tsai, Y. P., Wu, M. Z., Teng, S. C., Wu, K. J. (2012). Epigenetic reprogramming and post-transcriptional regulation during the epithelial-mesenchymal transition. Trends Genet, 28(9), 454-463. doi: 10.1016/j.tig.2012.05.005 Wu, J., Wong, W. W., Khosravi, F., Minden, M. D., Penn, L. Z. (2004). Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res, 64(18), 6461-6468. doi: 10.1158/0008-5472.CAN-04-0866 Wu, J. Y., Wu, S. G., Yang, C. H., Gow, C. H., Chang, Y. L., Yu, C. J., . . . Yang, P. C. (2008). Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clinical Cancer Research, 14(15), 4877-4882. doi: 10.1158/1078-0432.CCR-07-5123 Yagi, T., Takeichi, M. (2000). Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. Genes Dev, 14(10), 1169-1180. Yamada, M., Ohkusa, T., Okayasu, I. (1992). Occurrence of dysplasia and adenocarcinoma after experimental chronic ulcerative colitis in hamsters induced by dextran sulphate sodium. Gut, 33(11), 1521-1527. Yan, B., Zhang, W., Jiang, L. Y., Qin, W. X., Wang, X. (2014). Reduced E-Cadherin expression is a prognostic biomarker of non-small cell lung cancer: a meta-analysis based on 2395 subjects. International Journal of Clinical and Experimental Medicine, 7(11), 4352-4356. Yang, P. M., Liu, Y. L., Lin, Y. C., Shun, C. T., Wu, M. S., Chen, C. C. (2010). Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res, 70(19), 7699-7709. doi: 10.1158/0008-5472.CAN-10-1626 Yano, S., Wang, W., Li, Q., Matsumoto, K., Sakurama, H., Nakamura, T., . . . Sone, S. (2008). Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res, 68(22), 9479-9487. doi: 10.1158/0008-5472.CAN-08-1643 Yarden, Y., Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2(2), 127-137. doi: 10.1038/35052073 Yoo, C. B., Jones, P. A. (2006). Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov, 5(1), 37-50. doi: 10.1038/nrd1930 Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., . . . Riely, G. J. (2013). Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clinical Cancer Research, 19(8), 2240-2247. doi: 10.1158/1078-0432.CCR-12-2246 Zhou, W., Ercan, D., Chen, L., Yun, C. H., Li, D., Capelletti, M., . . . Janne, P. A. (2009). Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature, 462(7276), 1070-1074. doi: 10.1038/nature08622 Zimmerman, T., Blanco, F. J. (2008). Inhibitors targeting the LFA-1/ICAM-1 cell-adhesion interaction: design and mechanism of action. Curr Pharm Des, 14(22), 2128-2139. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52754 | - |
| dc.description.abstract | EGFR activating mutation在亞洲區非小細胞肺癌病患約占60%，EGFR-TKI如gefitinib與erlotinib可有效治療此類EGFR過度活化之病患，但通常約一年後會產生acquired resistance；為進一步探討acquired resistance之機轉，我們建立gefitinib resistance細胞株HCC827/IR，外觀具mesenchymal form 伴隨著E-cadherin 之downregulation和vimentin 之upregulation。 本實驗中，新穎HDAC抑制劑JMF3086可增加E-cadherin及減少vimentin 的表現。併用JMF3086 與gefitinib可克服gefitinib抗藥性並誘發細胞凋亡；併用JMF3086 與化療藥物cisplatin亦可以抑制細胞生長並誘發細胞凋亡。因此，JMF3086併用gefitinib或cisplatin具有潛力應用於gefitinib抗藥性之非小細胞肺癌病患。 發炎性腸道疾病(Inflammatory bowel disease) 包括克隆氏症(Crohn’s disease, CD)及潰瘍性結腸炎(Ulcerative colitis, UC)，病因包括免疫系統失衡、環境因子及遺傳因素，目前藥物僅能控制疾病未能完全治癒。本實驗中，statin-SAHA conjugated 之JMF compound在DSS動物模式，具有預防及治療潰瘍性結腸炎之效果。 | zh_TW |
| dc.description.abstract | Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Activating mutation of epidermal growth factor receptor (EGFR) is found in NSCLC and occurs frequently in East Asian. EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib and erlotinib have exhibited significant effect on EGFR-mutant NSCLC. Nevertheless, patients develop acquired resistance to TKI. To further explore the mechanism of acquired resistance in NSCLC, we developed gefitinib resistance cell line HCC827/IR that showed mesenchymal phenotype accompanied with low expression of E-cadherin and high expression of vimentin. In our study, a novel polypharmacological HDAC inhibitor, JMF3086 could induce E-cadherin and decrease vimentin expression. Here, we showed that combination of gefitinib and JMF3086 overcame gefitinib resistance and induce apoptosis. Patients with EGFR mutation have longer survival after second-line treatments with platinum-class drug cisplatin. We therefore combined cisplatin and JMF3086 and showed that their combination led to growth inhibition and apoptosis. Therefore, JMF 3086 combined with gefitinib or cisplatin might be potential therapies to overcome gefitinib resistance in NSCLC. Inflammatory bowel disease (IBD), which include Crohn's disease (CD) and ulcerative colitis (UC), is a complex disease mediated by genetic, immune, and environmental factors. Recently, medications to cure IBD is limited while animal models of intestinal inflammation provide a good way to further investigate the cause of IBD and possible medication. In this study, JMF compound, statin-SAHA conjugated compound had promising effect on prevention and treatment of IBD by using DSS-induced acute colitis mouse model. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T16:26:08Z (GMT). No. of bitstreams: 1 ntu-104-R02443020-1.pdf: 11504619 bytes, checksum: 465a9dba5a02c4b463defff78aa54482 (MD5) Previous issue date: 2015 | en |
| dc.description.tableofcontents | 目錄……………………………………………………………………………………1 縮寫……………………………………………………………………………………2 中文摘要………………………………………………………………………………5 Abstract………………………………………………………………………………..6 第一部分 第一章緒論……………………………………………………………………………7 第一節 非小細胞肺癌………………………………………………………………..8 第二節 對小分子藥物TKI之抗藥性………………………………………………20 第三節 HDAC抑制劑與HMGR抑制劑…………………………………………...31 第四節 Epithelial mesenchymal transition and Cancer stem cells………………….44 研究動機……………………………………………………………………………..53 第二章 實驗材料與方法……………………………………………………………54 第三章 實驗結果……………………………………………………………………59 第四章 討論…………………………………………………………………………81 結論…………………………………………………………………………………..85 第二部分 第五章緒論…………………………………………………………………………..86 發炎性腸道疾病……………………………………………………………………..87 研究動機……………………………………………………………………………103 第六章 實驗材料與方法…………………………………………………………..104 第七章 實驗結果…………………………………………………………………..107 第八章 討論………………………………………………………………………..121 結論…………………………………………………………………………………123 參考資料……………………………………………………………………………124 | |
| dc.language.iso | zh-TW | |
| dc.subject | 新穎HDAC抑制劑 | zh_TW |
| dc.subject | Novel HDAC Inhibitor | en |
| dc.title | 新穎HDAC抑制劑在非小細胞肺癌與腸炎之研究 | zh_TW |
| dc.title | Effects of Novel HDAC Inhibitors on Non-Small Cell Lung Cancer and Colitis | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 103-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 吳明賢,施金元,黃偉謙 | |
| dc.subject.keyword | 新穎HDAC抑制劑, | zh_TW |
| dc.subject.keyword | Novel HDAC Inhibitor, | en |
| dc.relation.page | 135 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2015-08-14 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥理學研究所 | zh_TW |
| 顯示於系所單位： | 藥理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-104-1.pdf 未授權公開取用 | 11.23 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。